Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31049888 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL52706 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL31049893 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL31049856 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL1005765 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL24597734 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL3862786 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL47126 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL1703446 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 | |
| SCHEMBL31049851 | 1.00 | CYP1A2 (0.59) | CYP1A2ALDH1A1TRPA1DGKAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1088 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118546075-A | Isosteviol and steviol derivative containing hydroxamic acid groups as well as preparation method and application thereof | 新乡医学院 | 2024-08-27 | — | — | CN | claimed |
| CN-118221674-A | Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117003745-B | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2024-06-07 | — | — | CN | claimed |
| CN-117777049-B | Thiazolidinedione HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-117777049-A | Thiazolidinedione HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117567421-A | Dihydromyricetin derivative, preparation method and application thereof in preparation of medicines for inhibiting new coronaviruses | 湖南中医药大学 | 2024-02-20 | — | — | CN | claimed |
| CN-117003745-A | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2023-11-07 | — | — | CN | claimed |
| CN-116444447-B | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | claimed |
| CN-116444447-A | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | 中国药科大学 | 2023-07-18 | — | — | CN | claimed |
| CN-115850618-A | Dynamic cross-linked azobenzene liquid crystal elastomer with linear/star SBS block copolymer as main chain and preparation method thereof | 大连理工大学 | 2023-03-28 | — | — | CN | claimed |
| CN-111789964-B | Selenium polymer prodrug micelle with reduction responsiveness, preparation method and application | 南开大学 | 2022-05-27 | — | — | CN | claimed |
| CN-110003047-B | Method for preparing nitrile by reacting acetone cyanohydrin with alkyl halide | 哈尔滨理工大学 | 2022-05-06 | — | — | CN | claimed |
| CN-113173923-B | Self-assembled monomolecular layer type non-doped hole transport material and synthetic method and application thereof | 嘉兴学院 | 2022-04-22 | — | — | CN | claimed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| CN-113173923-A | Self-assembled monomolecular layer type non-doped hole transport material and synthetic method and application thereof | 嘉兴学院 | 2021-07-27 | — | — | CN | claimed |
| CN-111789964-A | Selenium polymer prodrug micelle with reduction responsiveness, preparation method and application | 南开大学 | 2020-10-20 | — | — | CN | claimed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | claimed |
| US-4088536-A | ALKYLATING LITHIUM CYCLOPENTADIENE, OXYGENATING TO PRODUCE HYDROXYCLYCLOPENTENONES, SEPARATION, MULTISTAGE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1978-05-09 | — | — | US | claimed |
| US-4031129-A | LITHIUM CYCLOPENTADIENE, ETHYL-7-BROMOHEPTANOATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-06-21 | — | — | US | claimed |
| EP-4747239-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4746874-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036697-A | Indole group and triazine group-containing derivative small molecule and application thereof | 中国药科大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124191-A1 | HISTONE DEACETYLASE INHIBITOR AND USES THEREOF | NANJING HONGSHUN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4731606-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4725940-A1 | HISTONE DEACETYLASE INHIBITOR AND USE | Nanjing Hongshun Pharmaceutical Technology Co., Ltd (CN) | 2026-04-15 | — | — | EP | disclosed |
| EP-4695266-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688761-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | Tonix Pharma Limited (IE) | 2026-02-11 | — | — | EP | disclosed |
| EP-3638678-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4598536-A2 | INDAZOLE PYRIDONE COMPOUNDS AND USES THEREOF | Bluejay Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| US-12358911-B2 | Heterocyclic comipound as CDK-HDAC dual pathway inhibitor | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2025-07-15 | — | — | US | disclosed |
| EP-4577526-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| CN-120051281-A | Indazole pyridone compounds and uses thereof | 蓝樫鸟医药公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120051461-A | VHH antibody conjugates | 雅博得乐医疗公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120040359-A | Azole selenourea carboxylate and preparation method and application thereof | 华南农业大学 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145607-A1 | Modulators of CAMKK2 as Ligand Directed Degraders | CELGENE CORPORATION (US) | 2025-05-08 | — | — | US | disclosed |
| CN-116082216-B | 3-Aryl indole KDM1A/HDACs double-target inhibitor, and preparation method and application thereof | 阜外华中心血管病医院 | 2025-04-11 | — | — | CN | disclosed |
| CN-115398219-B | Capillary gel electrophoresis and its use in complex biomolecules | 阿瑞斯贸易股份公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-117756742-B | Benzothiazole compound or salt thereof, preparation method and application thereof | 徐州医科大学 | 2025-03-04 | — | — | CN | disclosed |
| WO-2025035202-A1 | IONIZABLE LIPIDS COMPRISING MACROCYCLIC RINGS FOR THE DELIVERY OF THERAPEUTIC AGENTS | NANOVATION THERAPEUTICS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| EP-3394030-B2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-2025027089-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-118221674-B | Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| WO-2025019819-A2 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025019823-A1 | SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025011398-A1 | HISTONE DEACETYLASE INHIBITOR AND USE | 南京市鸿舜医药科技有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-118812558-B | Oxafibrauretine compound and its pharmaceutical use | 中国医学科学院医学实验动物研究所 | 2024-12-13 | — | — | CN | disclosed |
| US-20240358842-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. | 2024-10-31 | — | — | US | disclosed |
| WO-2024213143-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024206520-A1 | (S)-TIANEPTINE AND USE IN TREATING DISORDERS AND CONDITIONS ASSOCIATED WITH PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR | TONIX PHARMACEUTICALS HOLDING CORP. (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240327427-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-10-03 | — | — | US | disclosed |
| EP-4433464-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | Astrazeneca AB (SE) | 2024-09-25 | — | — | EP | disclosed |
| US-12077501-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118546075-A | Isosteviol and steviol derivative containing hydroxamic acid groups as well as preparation method and application thereof | 新乡医学院 | 2024-08-27 | — | — | CN | disclosed |
| EP-4412999-A1 | MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS | Celgene Corporation (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-116283817-B | NO donor type HDAC inhibitor, composition and application thereof | 安徽中医药大学 | 2024-08-02 | — | — | CN | disclosed |
| EP-3778704-B1 | METHOD FOR PRODUCING MULTI-ARM TYPE POLYETHYLENE GLYCOL DERIVATIVE | NOF CORP (JP) | 2024-07-31 | — | — | EP | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-113620890-B | Benzoquinoxalinone compound and synthesis method and application thereof | 普济生物科技（台州）有限公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118234713-A | Novel lipids for delivery of nucleic acid segments | 阿斯利康(瑞典)有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118221674-A | Pyrrolo [3,2-b ] pyridine Top/HDAC double-target inhibitor, preparation method, pharmaceutical composition and application thereof | 南京市鸿舜医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-117800921-B | Imidazolidine diketone HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-117003745-B | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2024-06-07 | — | — | CN | disclosed |
| US-20240182472-A1 | INDAZOLE PYRIDONE COMPOUNDS AND USES THEREOF | MIRUM PHARMACEUTICALS, INC. | 2024-06-06 | — | — | US | disclosed |
| CN-117777049-B | Thiazolidinedione HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240174637-A1 | DEGRADERS OF GRK2 AND USES THEREOF | PIIZZI GRAZIA (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076603-A | CAMKK2 modulators as ligand-directed degradants | 细胞基因公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4133263-B1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | ARES TRADING SA (CH) | 2024-05-22 | — | — | EP | disclosed |
| CN-113166148-B | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors | 杭州英创医药科技有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024077024-A2 | INDAZOLE PYRIDONE COMPOUNDS AND USES THEREOF | BLUEJAY THERAPEUTICS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240109852-A1 | Ferroptosis-HDAC Inhibitor Hybrid Anticancer Agents | THE UNIVERSITY OF TOLEDO (US) | 2024-04-04 | — | — | US | disclosed |
| CN-117800921-A | Imidazolidine diketone HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117776923-A | Crocetin diester compound and application thereof in liver cancer cell resistance | 常州大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777053-A | Industrial production method of tianeptine | 山东诚汇双达药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777049-A | Thiazolidinedione HDAC inhibitor, preparation method and application | 南京市鸿舜医药科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117756742-A | Benzothiazole compound or salt thereof, preparation method and application thereof | 徐州医科大学 | 2024-03-26 | — | — | CN | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044549-A1 | VHH ANTIBODY CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044554-A1 | VHH ANTIBODY CONJUGATES WITH HETEROARYL CHELATORS | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11905366-B2 | Method for producing multi-arm type polyethylene glycol derivative | NOF CORPORATION (JP) | 2024-02-20 | — | — | US | disclosed |
| CN-117567421-A | Dihydromyricetin derivative, preparation method and application thereof in preparation of medicines for inhibiting new coronaviruses | 湖南中医药大学 | 2024-02-20 | — | — | CN | disclosed |
| CN-115353495-B | Preparation method and application of furazolidone metabolite AOZ-derived hapten, complete antigen and serum antibody | 江西农业大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-115368306-B | HDAC inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | 安徽中医药大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-113620873-B | Preparation method and application of zinc-containing binding group and quinoline skeleton compound | 沈阳药科大学 | 2023-12-08 | — | — | CN | disclosed |
| EP-4281445-A1 | DEGRADERS OF GRK2 AND USES THEREOF | Sonata Therapeutics, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-111132963-B | Compound, composition, cured product, and method for producing cured product | 株式会社艾迪科 | 2023-11-24 | — | — | CN | disclosed |
| CN-116554079-B | Histone deacetylase inhibitor and application thereof | 南京市鸿舜医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117003745-A | GLS1/HDAC double-target inhibitor and synthetic method and application thereof | 南京市第一医院 | 2023-11-07 | — | — | CN | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| CN-113512058-B | Zwitterionic liquid silane coupling agent, synthetic method and application thereof | 中国科学院深圳先进技术研究院 | 2023-10-03 | — | — | CN | disclosed |
| CN-116832176-A | Liver targeting drug delivery carrier and preparation method and application thereof | 重庆第二师范学院 | 2023-10-03 | — | — | CN | disclosed |
| CN-116444447-B | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | 中国药科大学 | 2023-09-22 | — | — | CN | disclosed |
| WO-2022159688-A9 | DEGRADERS OF GRK2 AND USES THEREOF | SONATA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-3604383-B1 | PRODUCTION METHOD OF POLYOXYETHYLENE DERIVATIVE HAVING PLURALITY OF HYDROXYL GROUPS AT TERMINAL | NOF CORP (JP) | 2023-09-06 | — | — | EP | disclosed |
| CN-116554079-A | Histone deacetylase inhibitor and application thereof | 南京市鸿舜医药科技有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023137518-A1 | PLATINUM COMPLEXES | Western Sydney University (AU) | 2023-07-27 | — | — | WO | disclosed |
| US-20230227467-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2023-07-20 | — | — | US | disclosed |
| CN-116444447-A | SOS1 and HDAC double-target quinazoline hydroxamic acid compound as well as preparation method and application thereof | 中国药科大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-116283817-A | NO donor type HDAC inhibitor, composition and application thereof | 安徽中医药大学 | 2023-06-23 | — | — | CN | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| WO-2023089522-A1 | NOVEL LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-05-25 | — | — | WO | disclosed |
| US-20230152275-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | ARES TRADING S.A. (CH) | 2023-05-18 | — | — | US | disclosed |
| CN-116082216-A | 3-aryl indole KDM1A/HDACs double-target inhibitor, and preparation method and application thereof | 阜外华中心血管病医院 | 2023-05-09 | — | — | CN | disclosed |
| CN-113816936-B | Mangostin derivative compound and preparation method and application thereof | 广州长峰生物技术有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-11634434-B2 | Bifunctional alpha-synuclein binding agents and uses thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2023-04-25 | — | — | US | disclosed |
| WO-2023059873-A1 | MODULATORS OF CAMKK2 AS LIGAND DIRECTED DEGRADERS | CELGENE CORPORATION (US) | 2023-04-13 | — | — | WO | disclosed |
| CN-115850618-A | Dynamic cross-linked azobenzene liquid crystal elastomer with linear/star SBS block copolymer as main chain and preparation method thereof | 大连理工大学 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| CN-111936548-B | Method for producing multi-arm polyethylene glycol derivative | 日油株式会社 | 2023-03-21 | — | — | CN | disclosed |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11597732-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2023015797-A1 | ZWITTERIONIC LIQUID SILANE COUPLING AGENT, SYNTHESIS METHOD, AND USE THEREOF | 中国科学院深圳先进技术研究院 | 2023-02-16 | — | — | WO | disclosed |
| EP-4133263-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | Ares Trading S.A. (CH) | 2023-02-15 | — | — | EP | disclosed |
| WO-2023280026-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220402934-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-11518795-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-12-06 | — | — | US | disclosed |
| CN-115398219-A | Capillary gel electrophoresis and its use in complex biomolecules | 阿瑞斯贸易股份公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-115368306-A | HDAC (Histone deacetylase) inhibitor containing tetrahydroisoquinoline structure, composition and application thereof | 安徽中医药大学 | 2022-11-22 | — | — | CN | disclosed |
| CN-109824642-B | Chrysin phenylalanine derivative with anti-lung cancer activity | 南华大学 | 2022-10-21 | — | — | CN | disclosed |
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220242812-A1 | SWELL1-LRRC8 COMPLEX MODULATORS | WASHINGTON UNIVERSITY (US) | 2022-08-04 | — | — | US | disclosed |
| EP-4036079-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ModernaTX, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| WO-2022159688-A1 | DEGRADERS OF GRK2 AND USES THEREOF | CYGNAL THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-111253412-B | Alpha-mangostin derivative and application thereof | 广州中医药大学(广州中医药研究院) | 2022-07-22 | — | — | CN | disclosed |
| CN-111646973-B | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2022-07-19 | — | — | CN | disclosed |
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| CN-111789964-B | Selenium polymer prodrug micelle with reduction responsiveness, preparation method and application | 南开大学 | 2022-05-27 | — | — | CN | disclosed |
| CN-110003047-B | Method for preparing nitrile by reacting acetone cyanohydrin with alkyl halide | 哈尔滨理工大学 | 2022-05-06 | — | — | CN | disclosed |
| CN-112574188-B | Pyrazole compound and application thereof | 苏州爱科百发生物医药技术有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2022087456-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-114395027-A | Creatinine competitive antigen, preparation method thereof and method for detecting stability of creatinine competitive antigen | 无锡博慧斯生物医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113173923-B | Self-assembled monomolecular layer type non-doped hole transport material and synthetic method and application thereof | 嘉兴学院 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022079226-A1 | INHIBITORS OF PDEDELTA | UNIVERSITÉ DU LUXEMBOURG (LU) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079226-A1 | INHIBITORS OF PDEDELTA | UNIVERSITÉ DU LUXEMBOURG (LU) | 2022-04-21 | — | — | WO | disclosed |
| EP-2637698-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2022-04-20 | — | — | EP | disclosed |
| CN-110475801-B | Method for producing polyoxyethylene derivative having plural hydroxyl groups at terminal | 日油株式会社 | 2022-04-19 | — | — | CN | disclosed |
| EP-3979998-A1 | SWELL1-LRRC8 COMPLEX MODULATORS | Washington University (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114341128-A | Bifunctional protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114206327-A | SWELL1-LRRC8 complex modulators | 华盛顿大学 | 2022-03-18 | — | — | CN | disclosed |
| US-11274135-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2022-03-15 | — | — | US | disclosed |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2022-03-01 | — | — | US | disclosed |
| CN-108276373-B | Flavonoid compound and application thereof in anti-cancer drugs | 南开大学 | 2022-02-15 | — | — | CN | disclosed |
| US-20220024916-A1 | HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| WO-2022017442-A1 | BIFUNCTIONAL PROTEIN DEGRADATION-TARGETED CHIMERA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2022-01-27 | — | — | WO | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3394030-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| CN-113816936-A | Mangostin derivative compound and preparation method and application thereof | 广州长峰生物技术有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-113620890-A | Benzoquinoxalinone compounds, and synthesis method and application thereof | 普济生物科技（台州）有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620873-A | Preparation method and application of compound containing zinc binding group and quinoline skeleton | 沈阳药科大学 | 2021-11-09 | — | — | CN | disclosed |
| CN-113512058-A | Zwitterionic liquid silane coupling agent, synthetic method and application thereof | 中国科学院深圳先进技术研究院 | 2021-10-19 | — | — | CN | disclosed |
| EP-3892989-A1 | CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES | Ares Trading S.A. (CH) | 2021-10-13 | — | — | EP | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| CN-113173923-A | Self-assembled monomolecular layer type non-doped hole transport material and synthetic method and application thereof | 嘉兴学院 | 2021-07-27 | — | — | CN | disclosed |
| CN-113166148-A | Heterocyclic compounds as CDK-HDAC dual pathway inhibitors | 杭州英创医药科技有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-110600612-B | P-i-n type perovskite battery hole transport layer based on self-assembly engineering | 华东理工大学 | 2021-07-16 | — | — | CN | disclosed |
| US-20210214370-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2021-07-15 | — | — | US | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-2970154-B1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | US HEALTH (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-07-01 | — | — | US | disclosed |
| CN-111848629-B | mTOR/HDAC dual inhibitor and application thereof | 安徽中医药大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-109776549-B | Water-soluble conjugated oligomer functionalized porphyrin photosensitizer and preparation method and application thereof | 陕西师范大学 | 2021-06-04 | — | — | CN | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-20210161829-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2021-06-03 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| CN-112645971-A | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-04-13 | — | — | CN | disclosed |
| WO-2021057994-A1 | PYRAZOLE COMPOUND AND USE THEREOF | 苏州爱科百发生物医药技术有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574188-A | Pyrazole compound and application thereof | 苏州爱科百发生物医药技术有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10947343-B2 | Production method of polyoxyethylene derivative having plurality of hydroxyl groups at terminal | NOF CORPORATION (JP) | 2021-03-16 | — | — | US | disclosed |
| WO-2021027807-A1 | METHOD FOR PREPARING AZELAIC ACID | 新钰生技股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| EP-3778704-A1 | METHOD FOR PRODUCING MULTI-ARM TYPE POLYETHYLENE GLYCOL DERIVATIVE | NOF Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-107072993-B | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | 中外制药株式会社 | 2021-02-12 | — | — | CN | disclosed |
| US-20210024692-A1 | METHOD FOR PRODUCING MULTI-ARM TYPE POLYETHYLENE GLYCOL DERIVATIVE | NOF CORPORATION (JP) | 2021-01-28 | — | — | US | disclosed |
| US-10894795-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020252041-A1 | SWELL1-LRRC8 COMPLEX MODULATORS | WASHINGTON UNIVERSITY (US) | 2020-12-17 | — | — | WO | disclosed |
| EP-2911656-B1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2020-12-02 | — | — | EP | disclosed |
| CN-111936548-A | Method for producing multi-arm polyethylene glycol derivative | 日油株式会社 | 2020-11-13 | — | — | CN | disclosed |
| CN-111848629-A | mTOR/HDAC dual inhibitor and application thereof | 安徽中医药大学 | 2020-10-30 | — | — | CN | disclosed |
| US-20200339593-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2020-10-29 | — | — | US | disclosed |
| CN-107624113-B | Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of HBsAg (HBV surface antigen) and HBV DNA production for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-111789964-A | Selenium polymer prodrug micelle with reduction responsiveness, preparation method and application | 南开大学 | 2020-10-20 | — | — | CN | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10799463-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| CN-105392777-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2020-09-22 | — | — | CN | disclosed |
| CN-111646973-A | Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-09-11 | — | — | CN | disclosed |
| CN-106456580-B | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | 科罗拉多州立大学董事会法人团体 | 2020-09-04 | — | — | CN | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3013796-B9 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190019-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3321261-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020114519-A1 | HETEROCYCLIC COMPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | 杭州英创医药科技有限公司 | 2020-06-11 | — | — | WO | disclosed |
| US-10676482-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| CN-111253412-A | α -mangostin derivative and application thereof | 广州中医药大学(广州中医药研究院) | 2020-06-09 | — | — | CN | disclosed |
| CN-111166733-A | Resveratrol-fatty acid coupling compound and medical application thereof | 北京美倍他药物研究有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-111132963-A | Compound, composition, cured product, and method for producing cured product | 株式会社艾迪科 | 2020-05-08 | — | — | CN | disclosed |
| CN-107573498-B | Polyoxyethylene derivative having plural hydroxyl groups at terminal | 日油株式会社 | 2020-04-24 | — | — | CN | disclosed |
| US-20200123215-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2020-04-23 | — | — | US | disclosed |
| EP-3638678-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3628661-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEM, LTD. (KR) | 2020-04-01 | — | — | EP | disclosed |
| US-10604554-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| US-20200079903-A1 | PRODUCTION METHOD OF POLYOXYETHYLENE DERIVATIVE HAVING PLURALITY OF HYDROXYL GROUPS AT TERMINAL | NOF CORPORATION (JP) | 2020-03-12 | — | — | US | disclosed |
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2020-02-27 | — | — | US | disclosed |
| CN-108129364-B | Biphenyl ring compound, preparation method and medical application thereof | 中国药科大学 | 2020-02-07 | — | — | CN | disclosed |
| EP-3604383-A1 | METHOD FOR PRODUCING POLYOXYETHYLENE DERIVATIVE HAVING HYDROXY GROUPS AT TERMINAL | NOF Corporation (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-10550149-B2 | PPAR agonists and methods of use thereof | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| CN-110600612-A | P-i-n type perovskite battery hole transport layer based on self-assembly engineering | 华东理工大学 | 2019-12-20 | — | — | CN | disclosed |
| US-20190352310-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2019-11-21 | — | — | US | disclosed |
| US-RE47690-E1 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190322643-A1 | HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2019-10-24 | — | — | US | disclosed |
| EP-3553065-A1 | HETEROCYCLIC COMPOUND AS SYK INHIBITOR AND/OR SYK-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| WO-2019189431-A1 | METHOD FOR PRODUCING MULTI-ARM TYPE POLYETHYLENE GLYCOL DERIVATIVE | 日油株式会社 | 2019-10-03 | — | — | WO | disclosed |
| EP-2692771-B1 | POLYOXYETHYLENE DERIVATIVE HAVING A PLURALITY OF HYDROXYL GROUPS AT END | NOF CORP (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-10336770-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3292120-B1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-2046736-B1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10308700-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2019-06-04 | — | — | US | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10221138-B2 | Biaryl derivatives as GPR120 agonists | LG CHEM, LTD. (KR) | 2019-03-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180369419-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018232120-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-10150763-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2018-12-11 | — | — | US | disclosed |
| US-10137212-B2 | Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180334430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2018-11-22 | — | — | US | disclosed |
| US-20180333366-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-22 | — | — | US | disclosed |
| EP-3394030-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180305403-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-10-25 | — | — | US | disclosed |
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-09-20 | — | — | US | disclosed |
| US-20180244742-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2018-08-30 | — | — | US | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
| US-10000542-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2018-06-19 | — | — | US | disclosed |
| EP-2637699-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK AS (DK) | 2018-05-16 | — | — | EP | disclosed |
| EP-3321261-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| EP-2917202-B1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| EP-2917202-B1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2018-05-02 | — | — | EP | disclosed |
| EP-2554565-B1 | MULTIFUNCTIONAL POLYOXYALKYLENE COMPOUND, METHOD FOR PRODUCING SAME AND INTERMEDIATE OF SAME | NOF CORP (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-9938234-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-04-10 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180086750-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| WO-2018045464-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018045464-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2018-03-15 | — | — | WO | disclosed |
| EP-3292120-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | H. Hoffnabb-La Roche Ag (CH) | 2018-03-14 | — | — | EP | disclosed |
| US-9908971-B2 | Multi-arm polyethylene glycol derivative, intermediate thereof, and method for producing same | NOF CORPORATION (JP) | 2018-03-06 | — | — | US | disclosed |
| EP-2661425-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20180044352-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2018-02-15 | — | — | US | disclosed |
| US-9873667-B2 | Arylsulfanyl compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2018-01-23 | — | — | US | disclosed |
| WO-2018005799-A1 | HISTONE DEACETYLASE AND HISTONE METHYLTRANSFERASE INHIBITORS AND METHODS OF MAKING AND USE OF THE SAME | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20170362251-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9845322-B2 | Tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840520-B2 | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| EP-2391605-B1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2017-11-08 | — | — | EP | disclosed |
| EP-2391605-B1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2017-11-08 | — | — | EP | disclosed |
| CN-104519902-B | Double acylated GLP-1 derivatives | 诺和诺德股份有限公司 | 2017-10-27 | — | — | CN | disclosed |
| CN-107266558-A | The derivatives of GLP 1 | 诺沃—诺迪斯克有限公司 | 2017-10-20 | — | — | CN | disclosed |
| US-9758560-B2 | GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-09-12 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-08-10 | — | — | US | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9708299-B2 | Hedgehog antagonists having zinc binding moieties | GENENTECH, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708383-B2 | Double-acylated GLP-1 derivatives | NOVO NORDISK A/S (DK) | 2017-07-18 | — | — | US | disclosed |
| EP-2576699-B1 | NAPHTHOCYANINES FOR USE AS CONTRAST AGENTS | PHARMPUR GMBH (DE) | 2017-07-12 | — | — | EP | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9676765-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-9676765-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-9676765-B2 | Histone deacetylase inhibitors and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2017-06-13 | — | — | US | disclosed |
| US-20170145069-A1 | GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2017-05-25 | — | — | US | disclosed |
| CN-104411322-B | Double acylated GLP-1 derivatives | 诺和诺德股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| EP-2961741-B1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUND PARA LA INVESTIG MEDICA APLICADA (ES) | 2017-04-05 | — | — | EP | disclosed |
| EP-2846824-B1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-04-05 | — | — | EP | disclosed |
| US-20170081343-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081343-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-23 | — | — | US | disclosed |
| US-20170081343-A1 | Heterocyclic Hydroxamic Acids as Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-23 | — | — | US | disclosed |
| EP-3142652-A1 | HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF | The Regents of the University of Colorado, a body corporate (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2753642-B1 | GLP-1 DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-9573956-B2 | Compounds as dual inhibitors of phosphodiesterases and histone deacetylases | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2017-02-21 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| EP-2832765-B1 | MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVE, INTERMEDIATE THEREOF AND METHOD FOR PRODUCING SAME | NOF CORP (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| EP-3116876-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | Agency For Science, Technology And Research (SG) | 2017-01-18 | — | — | EP | disclosed |
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9492496-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| WO-2016177655-A1 | TETRAHYDROPYRIDOPYRIMIDINES AND TETRAHYDROPYRIDOPYRIDINES AS INHIBITORS OF HBSAG (HBV SURFACE ANTIGEN) AND HBV DNA PRODUCTION FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326317-A1 | MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVE, INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING SAME | NOF CORPORATION (JP) | 2016-11-10 | — | — | US | disclosed |
| US-20160326167-A1 | Novel Tetrahydropyridopyrimidines and Tetrahydropyridopyridines for the Treatment and Prophylaxis of Hepatitis B Virus Infection | HOFFMANN-LA ROCHE INC. (US) | 2016-11-10 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9480280-B2 | Taste modifiers | GIVAUDAN S.A. (CH) | 2016-11-01 | — | — | US | disclosed |
| CN-103200966-B | Double-acylated GLP-1 derivatives with linker | 诺沃—诺迪斯克有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-9446015-B2 | Quinone based nitric oxide donating compounds for ophthalmic use | NICOX SCIENCE IRELAND (IE) | 2016-09-20 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-RE46144-E1 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9428609-B2 | Multi-arm polyethylene glycol derivative, intermediate thereof, and method for producing same | NOF CORPORATION (JP) | 2016-08-30 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160168096-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| US-9340503-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS, LIMITED (GB) | 2016-05-17 | — | — | US | disclosed |
| EP-3013796-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG Life Sciences Ltd. (KR) | 2016-05-04 | — | — | EP | disclosed |
| WO-2016057322-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-2981522-A1 | PPAR AGONISTS | Salk Institute for Biological Studies (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160022844-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | The USA, as represented by the secretary, Department of Health & Human Service (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2970154-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2975030-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-07 | — | — | US | disclosed |
| US-20160002246-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-01-07 | — | — | US | disclosed |
| EP-2961741-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | Fundacion para la Investigacion Medica Aplicada (ES) | 2016-01-06 | — | — | EP | disclosed |
| EP-2802589-B1 | FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | NOVARTIS AG (CH) | 2016-01-06 | — | — | EP | disclosed |
| US-20150361074-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361074-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361074-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| WO-2015175813-A1 | HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015175813-A1 | HETEROCYCLIC HYDROXAMIC ACIDS AS PROTEIN DEACETYLASE INHIBITORS AND DUAL PROTEIN DEACETYLASE-PROTEIN KINASE INHIBITORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20150322001-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-12 | — | — | US | disclosed |
| US-20150322001-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-12 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| US-9169244-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150283106-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX SA (FR) | 2015-10-08 | — | — | US | disclosed |
| US-20150274678-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-01 | — | — | US | disclosed |
| WO-2015137887-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | WO | disclosed |
| EP-2917202-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | Karus Therapeutics Limited (GB) | 2015-09-16 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| EP-2911656-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | Nicox Science Ireland (IE) | 2015-09-02 | — | — | EP | disclosed |
| US-9115129-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9108929-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9102622-B2 | Fatty acid amide hydrolase inhibitors | UNIVERSITY OF CONNECTICUT (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-20150216882-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-08-06 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096627-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-9079821-B2 | Quinone based nitric oxide donating compounds | NICOX SCIENCE IRELAND (IE) | 2015-07-14 | — | — | US | disclosed |
| US-9073932-B2 | Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9061962-B2 | Quinone based nitric oxide donating compounds | NICOX SCIENCE IRELAND (IE) | 2015-06-23 | — | — | US | disclosed |
| US-20150152157-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2015-06-04 | — | — | US | disclosed |
| US-20150133374-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2015-05-14 | — | — | US | disclosed |
| US-9029568-B2 | Branched hetero polyfunctional polyoxyalkylene compound and intermediate thereof | NOF CORPORATION (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2707354-B1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX SCIENCE IRELAND (IE) | 2015-04-29 | — | — | EP | disclosed |
| CN-104519902-A | Double-acylated GLP-1 derivatives | NOVO NORDISK AS | 2015-04-15 | — | — | CN | disclosed |
| US-9006178-B2 | Double-acylated GLP-1 derivatives with a linker | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-9006217-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2015-04-14 | — | — | US | disclosed |
| US-20150094312-A1 | SUBSTITUTED PYRROLO[2,3-B]PYRAZINE COMPOUNDS AND THEIR USE | NOVARTIS PHARMACEUTICALS UK LIMITED (GB) | 2015-04-02 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| EP-2846823-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| EP-2846824-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2015-03-18 | — | — | EP | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980909-B2 | HDAC inhibiting derivatives of camptothecin | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150073155-A1 | MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVE, INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING SAME | NOF CORPORATION (JP) | 2015-03-12 | — | — | US | disclosed |
| CN-104411322-A | Double acylated GLP-1 derivatives | NOVO NORDISK AS | 2015-03-11 | — | — | CN | disclosed |
| US-8975401-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8952125-B2 | Polyoxyethylene derivative having plural hydroxyl groups at terminal end thereof | NOF CORPORATION (JP) | 2015-02-10 | — | — | US | disclosed |
| EP-2832765-A1 | MULTI-ARM POLYETHYLENE GLYCOL DERIVATIVE, INTERMEDIATE THEREOF AND METHOD FOR PRODUCING SAME | NOF Corporation (JP) | 2015-02-04 | — | — | EP | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| US-8937069-B2 | Substituted pyrrolo[2,3-B]pyrazine compounds and their use | NOVARTIS AG (CH) | 2015-01-20 | — | — | US | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| WO-2014209034-A1 | BIARYL DERIVATIVES AS GPR120 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2014-12-31 | — | — | WO | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140357642-A1 | IP receptor agonist heterocyclic compounds | NOVARTIS AG (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140342998-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX S.A. (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2802589-A1 | FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-2802585-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | Novartis AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| EP-1853547-B1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION AND STABILIZING METHOD OF CAPSINOID | AJINOMOTO KK (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2190287-B1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2014-10-29 | — | — | EP | disclosed |
| EP-2412706-B1 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARM CORP (KR) | 2014-10-29 | — | — | EP | disclosed |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2014-10-23 | — | — | US | disclosed |
| WO-2014164988-A1 | TETRAHYDROXAMATE CHELATORS OF ZIRCONIUM89 AND NIOBIUM90 FOR USE IN DIAGNOSTIC APPLICATIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140303083-A1 | GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2014-10-09 | — | — | US | disclosed |
| WO-2014165827-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2014-10-09 | — | — | WO | disclosed |
| US-8846912-B2 | Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8835484-B2 | Naphthocyanines for use as contrast agents | ALAMEDICS GMBH & CO. KG (DE) | 2014-09-16 | — | — | US | disclosed |
| WO-2014131855-A1 | NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2014-09-04 | — | — | WO | disclosed |
| EP-2771321-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | Chong Kun Dang Pharmaceutical Corp. (KR) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8816099-B2 | Polyfunctional polyoxyalkylene compound, and producing method and intermediate thereof | NOF CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2014-08-21 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-8802875-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-08-12 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8771818-B2 | Electrically conducting member for electrophotography, process cartridge and electrophotographic image forming apparatus | CANON KABUSHIKI KAISHA (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8765796-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8759557-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-8759557-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-8759557-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2014-06-24 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748458-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2014-06-10 | — | — | US | disclosed |
| US-8748458-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2014-06-10 | — | — | US | disclosed |
| US-8748458-B2 | Scriptaid isosteres and their use in therapy | KARUS THERAPEUTICS LIMITED (GB) | 2014-06-10 | — | — | US | disclosed |
| US-20140155606-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2014078895-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2014-05-30 | — | — | WO | disclosed |
| US-8735409-B2 | Quinazoline derivatives | ZHANG QIANG (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1318140-B9 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-20140135389-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX SA (FR) | 2014-05-15 | — | — | US | disclosed |
| WO-2014072714-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2014-05-15 | — | — | WO | disclosed |
| WO-2014072714-A1 | NOVEL HISTONE DEACETYLASE INHIBITORS AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LTD (GB) | 2014-05-15 | — | — | WO | disclosed |
| US-20140128410-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8716435-B2 | Multibranched polyoxyalkylene compound and producing method thereof | NOF CORPORATION (JP) | 2014-05-06 | — | — | US | disclosed |
| WO-2014063923-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS FOR OPHTHALMIC USE | NICOX S.A. (FR) | 2014-05-01 | — | — | WO | disclosed |
| EP-2722326-A1 | Quinone based nitric oxide donating compounds | NICOX S.A. (FR) | 2014-04-23 | — | — | EP | disclosed |
| EP-2707354-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | Nicox S.A. (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2692771-A1 | POLYOXYETHYLENE DERIVATIVE HAVING A PLURALITY OF HYDROXYL GROUPS AT END | NOF Corporation (JP) | 2014-02-05 | — | — | EP | disclosed |
| US-20140031287-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MIC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20140018368-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GENETECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140005391-A1 | QUINAZOLINE BASED EGFR INHIBITORS | CURIS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130338167-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-20130338068-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK A/S (DK) | 2013-12-19 | — | — | US | disclosed |
| US-8609864-B2 | Hydroxamic acid derivatives | PURDUE PHARMACEUTICAL PRODUCTS, L.P. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20130330457-A1 | Taste Modifiers | GIVAUDAN S.A. (CH) | 2013-12-12 | — | — | US | disclosed |
| US-8604044-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2013167455-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013167454-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-11-14 | — | — | WO | disclosed |
| EP-2661425-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| US-20130288960-A1 | Double-Acylated GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| US-8569529-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-10-29 | — | — | US | disclosed |
| US-20130281402-A1 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281402-A1 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281275-A1 | ELECTRICALLY CONDUCTING MEMBER FOR ELECTROPHOTOGRAPHY, PROCESS CARTRIDGE AND ELECTROPHOTOGRAPHIC IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20130281484-A1 | HDAC Inhibitors and Therapeutic Methods of Using Same | UNIV ILLINOIS (US) | 2013-10-24 | — | — | US | disclosed |
| US-8563741-B2 | CDK inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2415800-B1 | HYPERBRANCHED POLYOXYALKYLENE COMPOUND AND METHOD FOR PRODUCING SAME | NOF CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8552039-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP-1) compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2637699-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | Novo Nordisk A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| EP-2637698-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | Novo Nordisk A/S (DK) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130237720-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-09-12 | — | — | US | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8518910-B2 | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-07-25 | — | — | US | disclosed |
| WO-2013105065-A1 | FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013105057-A1 | FUSED PYRROLES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS | NOVARTIS AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130184282-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-07-18 | — | — | US | disclosed |
| CN-101534831-B | Tyrosine inhibitors containing a zinc binding moiety | CURIS INC | 2013-07-17 | — | — | CN | disclosed |
| CN-103200966-A | Double-acylated GLP-1 derivatives with linker | NOVO NORDISK AS | 2013-07-10 | — | — | CN | disclosed |
| US-20130172576-A1 | BRANCHED HETERO POLYFUNCTIONAL POLYOXYALKYLENE COMPOUND AND INTERMEDIATE THEREOF | NOF CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20130158283-A1 | Process for the Preparation of Oxidized Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| US-8466161-B2 | Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-06-18 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2061469-B1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2013-06-05 | — | — | EP | disclosed |
| US-8455506-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130131354-A1 | Naphthocyanines for Use as Contrast Agents | AIAMEDICS GmbH & Co. KG (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2013060673-A1 | QUINONE BASED NITRIC OXIDE DONATING COMPOUNDS | NICOX S.A. (FR) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013062344-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-05-02 | — | — | WO | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102595-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. | 2013-04-25 | — | — | US | disclosed |
| US-8426419-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426356-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-2576699-A1 | NAPHTHOCYANINES FOR USE AS CONTRAST AGENTS | ALAMEDICS GMBH & CO. KG (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-8410309-B2 | Phenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| US-20130079540-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2013-03-28 | — | — | US | disclosed |
| WO-2013037690-A1 | GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2013-03-21 | — | — | WO | disclosed |
| US-8399452-B2 | Anticancer agents; antiproliferative agenst; antiprotozoa agents | METHYLGENE INC. (CA) | 2013-03-19 | — | — | US | disclosed |
| CN-102970868-A | Treatment of cancers having K-RAS mutations | CURIS INC | 2013-03-13 | — | — | CN | disclosed |
| EP-2557923-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | Curis, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ZHANG QIANG (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2554565-A1 | MULTIFUNCTIONAL POLYOXYALKYLENE COMPOUND, METHOD FOR PRODUCING SAME AND INTERMEDIATE OF SAME | NOF Corporation (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-8367663-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8349856-B2 | Quinazoline based EGFR inhibitors | CURIS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120322955-A1 | POLYOXYETHYLENE DERIVATIVE HAVING PLURAL HYDROXYL GROUPS AT TERMINAL END THEREOF | NOF CORPORATION (JP) | 2012-12-20 | — | — | US | disclosed |
| WO-2012170827-A2 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| EP-2522672-A1 | Oxidized phospholipids | Vascular Biogenics Ltd. (IL) | 2012-11-14 | — | — | EP | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2489657-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202773-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| WO-2012096832-A2 | HDAC INHIBITING DERIVATIVES OF CAMPTOTHECIN | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012094328-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| US-8207223-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8198454-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-12 | — | — | US | disclosed |
| EP-2456757-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120130108-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2012-05-24 | — | — | US | disclosed |
| WO-2012062803-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062804-A1 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER | NOVO NORDISK A/S (DK) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122881-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-8124800-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2012-02-28 | — | — | US | disclosed |
| US-8119616-B2 | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| EP-2415800-A1 | HYPERBRANCHED POLYOXYALKYLENE COMPOUND AND METHOD FOR PRODUCING SAME | NOF Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120028963-A1 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2012-02-02 | — | — | US | disclosed |
| EP-2412706-A2 | NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-8093282-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | KARUS THERAPEUTICS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | KARUS THERAPEUTICS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | KARUS THERAPEUTICS LIMITED (GB) | 2011-12-15 | — | — | US | disclosed |
| EP-2391605-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | Karus Therapeutics Limited (GB) | 2011-12-07 | — | — | EP | disclosed |
| EP-2389375-A2 | HYDROXAMIC ACID DERIVATIVES | Northlake Biosciences LLC (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8067136-B2 | Charge control agent, toner, image forming method, and image forming apparatus | CANON KABUSHIKI KAISHA (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| US-20110288070-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-11-24 | — | — | US | disclosed |
| EP-2385832-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | Curis, Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269706-A1 | Hydroxamic Acid Derivatives | NORTHLAKE BIOSCIENCES LLC (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011130628-A1 | TREATMENT OF CANCERS HAVING K-RAS MUTATIONS | CURIS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-8040979-B2 | Generating a phase value for a complex signal | INFINEON TECHNOLOGIES AG (DE) | 2011-10-18 | — | — | US | disclosed |
| US-8038101-B2 | Attitude change control method, attitude change control system, attitude change control program and program recording medium | NEC TOSHIBA SPACE SYSTEMS, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110245509-A1 | POLYFUNCTIONAL POLYOXYALKYLENE COMPOUND, AND PRODUCING METHOD AND INTERMEDIATE THEREOF | NOF CORPORATION (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-2367806-A2 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF 7-((3-CHLORO-6-METHYL-5,5-DIOXO-6,11-DIHYDRODIBENZO(C,F)(1,2) THIAZEPIN-11-YL)AMINO)HEPTANOATE | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2011-09-28 | — | — | EP | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
| US-20110196147-A1 | INHIBITORS OF HISTONE DEACETYLASE | FMR LLC | 2011-08-11 | — | — | US | disclosed |
| EP-2348866-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | Vascular Biogenics Ltd. (IL) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178095-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2011084796-A2 | NOVEL QUINAZOLINE DERIVATIVES | ZHANG QIANG | 2011-07-14 | — | — | WO | disclosed |
| EP-2343286-A1 | Dibenzo[b,f][1,4]oxazepine derivatives as inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2011-07-13 | — | — | EP | disclosed |
| US-7977347-B2 | inhibitors of epidermal growth factor receptor tyrosine kinase; anticancer; 6-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)hexanoic acid | CURIS, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010052718-A9 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-06-16 | — | — | WO | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-20110136902-A1 | 12-MEMBERED-RING MACROLACTAM DERIVATIVES | MIYANO MASAYUKI | 2011-06-09 | — | — | US | disclosed |
| US-7956051-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7951971-B1 | Phenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2320734-A1 | FLAVIN DERIVATIVES | BioRelix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-1318140-B1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-05-18 | — | — | EP | disclosed |
| US-20110112110-A1 | ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITA' DEGLISTUDI DI MILANO- BICOCCA (IT) | 2011-05-12 | — | — | US | disclosed |
| US-20110077399-A1 | Substituted Azole Derivatives as Therapeutic Agents | TRANSTECH PHARMA, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7915316-B2 | Sulfonamides | ALLERGAN, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2049467-B1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN INC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20110053963-A1 | TARTRATE SALTS OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CAI XIONG | 2011-03-03 | — | — | US | disclosed |
| EP-1417975-B1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP4 AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2011-03-02 | — | — | EP | disclosed |
| EP-2285782-A2 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | Allergan, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| US-7888361-B2 | anticancer; inhibits both BCR-ABL and histone deacetylase activity; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-(hydroxyamino)-2-oxoethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | CURIS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7887835-B2 | for vascular lesion imaging and for diagnosing arteriosclerosis, ischemia with X-ray angiography and positron emission tomography; fluorinated steroid ester, glyceride compounds, phosphatidylcholine, and phosphatidylserine as membrane components of liposome | FUJIFILM CORPORATION (JP) | 2011-02-15 | — | — | US | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
| EP-2272817-A1 | PAI-1 INHIBITOR | Institute of Medicinal Molecular Design, Inc. (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-7858825-B2 | Acid and base stable diphenylmethanol derivatives and methods of use | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-7855297-B2 | Amide derivatives and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2010-12-16 | — | — | US | disclosed |
| US-7846938-B2 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2255829-A2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | Ono Pharmaceutical Co., Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| EP-2247583-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010126030-A1 | SPIROIMIDAZOLONE DERIVATIVE | 中外製薬株式会社 (JP) | 2010-11-04 | — | — | WO | disclosed |
| US-20100261863-A1 | MULTIBRANCHED POLYOXYALKYLENE COMPOUND AND PRODUCING METHOD THEREOF | NOF CORPORATION (JP) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261710-A1 | HDAC Inhibitors | ARQULE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| US-7807847-B2 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2010-10-05 | — | — | US | disclosed |
| EP-2229386-A1 | AMINOTHIAZOLES AND THEIR USES | Novartis AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100234379-A1 | Dual modulation of endocannabinoid transport and fatty-acid amide hydrolase for treatment of excitotoxicity | CONNECTICUT, UNIVERSITY OF | 2010-09-16 | — | — | US | disclosed |
| CN-101835375-A | Vegfr inhibitors containing a zinc binding moiety | CURIS INC | 2010-09-15 | — | — | CN | disclosed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100222343-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2010-09-02 | — | — | US | disclosed |
| WO-2010086646-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086646-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | KARUS THERAPEUTICS LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010085377-A2 | HYDROXAMIC ACID DERIVATIVES | CRYSTAL BIOPHARMACEUTICAL LLC (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| WO-2010080996-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2205585-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| EP-2203058-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2203412-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2010-07-07 | — | — | EP | disclosed |
| US-7745646-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| WO-2010070667-A2 | NOVEL PROCESS FOR THE PREPARATION OF 7-((3-CHLORO-6-METHYL-5,5-DIOXO-6,11-DIHYDRODIBENZO(C,F)(1,2) THIAZEPIN-11-YL)AMINO)HEPTANOATE | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152291-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | AJINOMOTO CO., INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2194787-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2010-06-16 | — | — | EP | disclosed |
| EP-2190287-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2190845-A2 | HDAC INHIBITORS | ArQule, Inc. (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010052718-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7700331-B2 | Production method of capsinoid by dehydrating condensation, stabilizing method of capsinoid, and capsinoid composition | AJINOMOTO CO., INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-7683185-B2 | Histone deacetylase inhibitors | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2010-03-23 | — | — | US | disclosed |
| WO-2009026446-A9 | HDAC INHIBITORS | ARQULE, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-2091538-B1 | 4-BENZYL-1(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2010-03-03 | — | — | EP | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041656-A1 | Novel amide derivatives and medicinal use thereof | NAKAMURA MITSUBARU | 2010-02-18 | — | — | US | disclosed |
| US-7662771-B2 | Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (GLP)-1 compound or a melanocortin-4 receptor (MC4) agonist peptide | EMISPHERE TECHNOLOGIES, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145886-A1 | TWELVE-MEMBERED CYCLOMACROLACTAM DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-20100010222-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DISEASES ASSOCIATED WITH DECREASE IN BONE MASS COMPRISING EP4 AGONIST AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | UNIVERSIDAD DE GRANADA (ES) | 2009-12-17 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090306016-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT | 2009-12-10 | — | — | US | disclosed |
| EP-2125838-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | Vascular Biogenics Ltd. (IL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009137339-A2 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281102-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7608637-B2 | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20090258817-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | NOVO NORDISK A/S (DK) | 2009-10-15 | — | — | US | disclosed |
| WO-2009121535-A2 | ANTIPROLIFERATIVE COMPOUNDS AND THERAPEUTIC USES THEREOF | UNIVERSITA`DEGLI STUDI DI MILANO - BICOCCA (IT) | 2009-10-08 | — | — | WO | disclosed |
| EP-2107054-A1 | Antiproliferative compounds and therapeutic uses thereof | Università Degli Studi Di Milano - Bicocca (IT) | 2009-10-07 | — | — | EP | disclosed |
| CN-101534831-A | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS INC (US) | 2009-09-16 | — | — | CN | disclosed |
| US-7589156-B2 | Polyhydroxyalkanoic acid having ester, carboxyl or sulfonic acid group, and producing method therefor | CANON KABUSHIKI KAISHA (JP) | 2009-09-15 | — | — | US | disclosed |
| EP-1581535-B3 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-2091538-A2 | 4-BENZYL-L(2H)-PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | Glaxo Group Limited (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-20090209758-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | QIAN CHANGGENG | 2009-08-20 | — | — | US | disclosed |
| US-7576112-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20090202927-A1 | Charge control agent, toner, image forming method, and image forming apparatus | CANON KABUSHIKI KAISHA (JP) | 2009-08-13 | — | — | US | disclosed |
| WO-2009094286-A1 | HYDRAZINES IN GLAUCOMA THERAPY | ALLERGAN, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192151-A1 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192192-A1 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | TOUCH BIONICS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2009086012-A1 | AURORA INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-7557176-B2 | Polyhydroxyalkanoic acid having vinyl, ester, carboxyl or sulfonic acid group and producing method therefor | CANON KABUSHIKI KAISHA (JP) | 2009-07-07 | — | — | US | disclosed |
| US-7553922-B2 | Polyhydroxyalkanoate having ester group, carboxyl group, and sulfonic group, and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2009-06-30 | — | — | US | disclosed |
| WO-2009077844-A2 | INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA | QUONOVA LLC (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | OLD DAVID W | 2009-06-25 | — | — | US | disclosed |
| WO-2009074605-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090156628-A1 | Aminothiazoles and their Uses | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7547781-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2009-06-16 | — | — | US | disclosed |
| WO-2009065926-A2 | NEW ANTICANCER COMPOUNDS | SULFIDRIS S.R.L. (IT) | 2009-05-28 | — | — | WO | disclosed |
| EP-2061468-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061469-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1758948-B1 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KK (JP) | 2009-05-13 | — | — | EP | disclosed |
| US-20090111772-A1 | FORMULATION OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-30 | — | — | US | disclosed |
| EP-2051964-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | University of Connecticut (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052320-A1 | METHODS AND COMPOUNDS FOR MODULATING CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052319-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2009-04-23 | — | — | WO | disclosed |
| EP-2049495-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | Allergan, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049467-A2 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | Allergan, Inc. (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| EP-2046736-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| EP-1226104-B1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2009-04-08 | — | — | EP | disclosed |
| EP-2045246-A1 | DERIVATIVES OF BENZO[D] ISOTHIAZOLES AS HISTONE DEACETYLASE INHIBITORS | Universidad De Granada (ES) | 2009-04-08 | — | — | EP | disclosed |
| US-7510813-B2 | Resin-coated carrier for electrophotographic developer | CANON KABUSHIKI KAISHA (JP) | 2009-03-31 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| WO-2009035718-A1 | TARTRATE SALTS OR COMPLEXES OF QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036055-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036012-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036051-A1 | BCL-2 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036066-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009036020-A1 | MEK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036016-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076006-A1 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076044-A1 | VEGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-7504477-B2 | Polyalkylene glycol acid additives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2009026446-A2 | HDAC INHIBITORS | ARQULE, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1716113-B1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LTD (GB) | 2009-02-25 | — | — | EP | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| US-7470768-B2 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group, and sulfonic group, and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2008-12-30 | — | — | US | disclosed |
| US-7468360-B2 | Therapeutic amides and related compounds | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1774410-B1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KK (JP) | 2008-11-19 | — | — | EP | disclosed |
| EP-1492776-B1 | IODINATED TRIGLYCERIDE ANALOGS | FUJIFILM CORP (JP) | 2008-10-29 | — | — | EP | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080234297-A1 | HSP90 Inhibitors Containing a Zinc Binding Moiety | CURIS, INC. | 2008-09-25 | — | — | US | disclosed |
| WO-2008115262-A2 | HSP90 INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080214448-A1 | Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide | EMISPHERE TECHNOLOGIES INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-20080207590-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| WO-2008100564-A1 | LTA4H MODULATORS AND USES THEROF | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| US-20080200719-A1 | Acid and base stable diphenylmethanol derivatives and methods of use | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-08-21 | — | — | US | disclosed |
| EP-1660492-B1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-20 | — | — | EP | disclosed |
| US-7414071-B2 | Methods of treatment with selective EP4 receptor agonists | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194630-A1 | Leukotriene A-4 hydrolase inhibitors; antiinflammatory agents; skin disorders; analgesics; stroke; anticancer agents; antiallergens; rhinitis;cystic fibrosis;sepsis | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008084472-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008084472-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2008-07-17 | — | — | WO | disclosed |
| US-20080161320-A1 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-07-03 | — | — | US | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| US-20080139590-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080138285-A1 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | FUJIFILM CORPORATION (JP) | 2008-06-12 | — | — | US | disclosed |
| US-20080125440-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-7378480-B2 | Polymerizable compound, polymer compound, composition using such compound, and image forming method and apparatus | CANON KABUSHIKI KAISHA (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7371877-B2 | Glycerol ester derivative | FUJIFILM CORPORATION (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
| EP-1917238-A2 | SULFONAMIDES | Allergan, Inc. (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1916255-A2 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | FUJIFILM Corporation (JP) | 2008-04-30 | — | — | EP | disclosed |
| WO-2008033748-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033745-A2 | FUSED BICYCLIC PYRIMIDINES AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033746-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1581535-B9 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-03-19 | — | — | EP | disclosed |
| US-20080064828-A1 | Polyhydroxyalkanoic Acid Having Vinyl, Ester, Carboxyl or Sulfonic Acid Group and Producing Method Therefor | CANON KABUSHIKI KAISHA (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | ALLERGAN, INC. | 2008-02-28 | — | — | US | disclosed |
| WO-2008021933-A2 | N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES AS PROSTAGLANDINE RECEPTOR INHIBITORS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045596-A1 | Ep2 Receptor Agonists | ASTERAND, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2008021804-A2 | THERAPEUTIC AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008013963-A2 | FATTY ACID AMIDE HYDROLASE INHIBITORS | UNIVERSITY OF CONNECTICUT (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2008014430-A1 | ARYLSULFANYL COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| WO-2008006051-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| EP-1426353-B1 | 1,3-GLYCERIDE COMPOUND HAVING TWO IODOPHENYL GROUPS | FUJIFILM CORP (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1853547-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | Ajinomoto Co., Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1581535-B1 | PYRROLOPYRIDAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1339678-B1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PROD INC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7264790-B2 | 1,3-glyceride compound having two iodophenyl groups | FUJIFILM CORPORATION (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| US-20070155912-A1 | Polyhydroxyalkanoate having ester group, carboxyl group, and sulfonic group, and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070142471-A1 | SULFONAMIDES | ALLERGAN, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070117937-A1 | Polyhydroxyalkanoic acid having ester, carboxyl or sulfonic acid group and producing method thereor | CANON KABUSHIKI KAISHA (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070112211-A1 | Process for the preparation of oxidized phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-RE39634-E1 | Bisarylimidazoly fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1774410-A1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | Canon Kabushiki Kaisha (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070073006-A1 | Polyhydroxyalkanoate having vinyl group, ester group, carboxyl group, and sulfonic group, and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2007-03-29 | — | — | US | disclosed |
| US-7193031-B2 | Polyalkylene glycol acid additives | HOFFMANN-LA ROCHE INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-7192979-B2 | EP4 receptor selective agonist in the treatment of osteoporosis | PFIZER INC. (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1758948-A2 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | Canon Kabushiki Kaisha (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2007024860-A2 | SULFONAMIDES | ALLERGAN, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070020738-A1 | produced in a high yield in a short time using an enzyme; capsinoid can be stably preserved by coexistence of a fatty acid; enables industrially production | AJINOMOTO CO., INC (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005012297-A9 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-04 | — | — | WO | disclosed |
| EP-1658273-B1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | LILLY CO ELI (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7153854-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| US-20060270721-A1 | EP4 receptor agonist, compositions and methods thereof | HAN YONGXIN | 2006-11-30 | — | — | US | disclosed |
| US-20060264513-A1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-11-23 | — | — | US | disclosed |
| CN-1863768-A | Prostaglandin analogs as agonists of the EP4 receptor | HOFFMANN LA ROCHE (CH) | 2006-11-15 | — | — | CN | disclosed |
| EP-1716113-A1 | EP2- RECEPTOR AGONISTS | ASTERAND UK LIMITED (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-7129274-B1 | Phenoxy carboxylic acid compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060235231-A1 | 6-(4-Dimethylamino-phenylsulfanyl)-hexa-2,4-dienoic acid methyl ester; stimulating hematopoietic cells ex vivo | UCL BIOMEDICA PLC (GB) | 2006-10-19 | — | — | US | disclosed |
| US-7109223-B2 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma | MERCK & CO. INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060194071-A1 | Developer carrying member and development apparatus | CANON KABUSHIKI KAISHA (JP) | 2006-08-31 | — | — | US | disclosed |
| WO-2006088239-A1 | PRODUCTION METHOD OF CAPSINOID BY DEHYDRATING CONDENSATION, STABILIZING METHOD OF CAPSINOID, AND CAPSINOID COMPOSITION | AJINOMOTO CO., INC. (JP) | 2006-08-24 | — | — | WO | disclosed |
| EP-1487437-B1 | USE OF SELECTIVE EP4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASES | PFIZER PROD INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20060167218-A1 | Polyalkylene glycol acid additives | HOFFMANN-LA ROCHE INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060154899-A1 | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma | MERCK FROSST CANADA LTD. (CA) | 2006-07-13 | — | — | US | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20060128636-A1 | Breast cancer resistance protein (bcrp) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-0946501-B1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660492-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660491-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| EP-1658273-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060062726-A1 | with iodophenyl group (radioisotope), as a membrane component of liposomes, which enables lesion-selective contrast X-ray radiography of a vascular disease; metabolized in the liver, not accumulated in living bodies | FUJIFILM CORPORATION (JP) | 2006-03-23 | — | — | US | disclosed |
| US-7008636-B2 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH (US) | 2006-03-07 | — | — | US | disclosed |
| US-6998423-B2 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. (US) | 2006-02-14 | — | — | US | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1409455-B1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-01-04 | — | — | EP | disclosed |
| US-20050287484-A1 | Resin-coated carrier for electrophotographic developer | CANON KABUSHIKI KAISHA (JP) | 2005-12-29 | — | — | US | disclosed |
| WO-2005121904-A1 | CHARGE CONTROL AGENT, TONER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121204-A2 | POLYHYDROXYALKANOIC ACID HAVING VINYL, ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121207-A2 | POLYHYDROXYALKANOATE HAVING VINYL GROUP, ESTER GROUP, CARBOXYL GROUP, AND SULFONIC GROUP, AND METHOD OF PRODUCING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121208-A1 | POLYHYDROXYALKANOIC ACID HAVING ESTER, CARBOXYL OR SULFONIC ACID GROUP AND PRODUCING METHOD THEREFOR | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121205-A2 | POLYHYDROXYALKANOATE HAVING ESTER GROUP, CABOXYL GROUP, AND SULFONIC GROUP, AND METHOD OF PRODUCING THE SAME | CANON KABUSHIKI KAISHA (JP) | 2005-12-22 | — | — | WO | disclosed |
| EP-1594847-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | Transtech Pharma, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1591117-A1 | BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR | Kabushiki Kaisha Yakult Honsha (JP) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004071447-A9 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1389107-A4 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| US-20050209336-A1 | EP2 receptor agonists | ASTERAND, INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1565432-A1 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005061449-A1 | EP2 RECEPTOR AGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2005-07-07 | — | — | WO | disclosed |
| EP-1545517-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | Merck Frosst Canada & Co. (CA) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004046094-A9 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2005-06-23 | — | — | WO | disclosed |
| US-6900336-B2 | 8-aza-11-deoxy prostaglandin analogues | SYNTEX (U.S.A.) LLC (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1526872-A1 | POLYALKYLENE GLYCOL ACID ADDITIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-04 | — | — | EP | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| WO-2005019184-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON LIKE PEPTIDE (GLP)-1 COMPOUND OR AN MELANOCORTIN 4 RECEPTOR (MC4) AGONIST PEPTIDE | ELI LILLY AND COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043379-A1 | LTA4H Modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| US-20050043378-A1 | Leukotriene hydrolases inhibitors; antiinflamamtory agents; inflamamtory bowel disorders; antihistamines; chronic obstructive pulmonary diseases; multiple sclerosis; antiarthritic agents | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012297-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005012296-A1 | BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-10 | — | — | WO | disclosed |
| US-20050027037-A1 | Polymerizable compound, polymer compound composition using such compound, and image forming method and apparatus | CANON KABUSHIKI KAISHA (JP) | 2005-02-03 | — | — | US | disclosed |
| US-20050020686-A1 | Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| US-20050002864-A1 | 1,3-glyceride compound having two iodophenyl groups | FUJIFILM CORPORATION (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1492776-A2 | IODINATED TRIGLYCERIDE ANALOGS | Fuji Photo Film Co. Ltd. (JP) | 2005-01-05 | — | — | EP | disclosed |
| WO-2004110989-A1 | N-HYDROXY-7-(ARYLAMINO)HEPTANAMIDE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040259921-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
| EP-1487437-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | Pfizer Products Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
| US-20040214869-A1 | 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2004-10-28 | — | — | US | disclosed |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-30 | — | — | US | disclosed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040186151-A1 | Substituted azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-6790971-B1 | AMIDE OR CARBAMATE FUNCTION AT 11 BETA-POSITION; CLAIMED 3-ONE-DIENE INTERMEDIATE HAS HYDROXYMETHYLALKYL GROUP ON 11 POSITION; ANTIPROGESTOMIMETIC; HORMONE-DEPENDENT TUMORS; ANIMAL HUSBANDRY | AVENTIS PHARMA S.A. (FR) | 2004-09-14 | — | — | US | disclosed |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC | 2004-09-09 | — | — | US | disclosed |
| WO-2004071447-A2 | SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071448-A2 | SUBSTITUTED AZOLE DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | TRANSTECH PHARMA INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-6765021-B2 | ANTIDIABETIC AGENTS | WYETH | 2004-07-20 | — | — | US | disclosed |
| US-20040138223-A1 | Novel amide derivatives and medicinal use thereof ugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1426353-A1 | 1,3-minus;GLYCERIDE COMPOUND HAVING TWO IODOPHENYL GROUPS | Fuji Photo Film Co. Ltd. (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-6747054-B2 | FOR THERAPY OF LOW BONE MASS, PARTICULARLY OSTEOPOROSIS, FRAILTY, AN OSTEOPOROTIC FRACTURE, A BONE DEFECT, CHILDHOOD IDIOPATHIC BONE LOSS, ALVEOLAR BONE LOSS, MANDIBULAR BONE LOSS, BONE FRACTURE, OSTEOTOMY | PFIZER INC. | 2004-06-08 | — | — | US | disclosed |
| WO-2004046094-A1 | HISTONE DEACETYLASE INHIBITORS | QUEEN MARY & WESTFIELD COLLEGE (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-20040106747-A1 | Polyalkylene glycol acid additives | HOFFMANN-LA ROCHE INC. | 2004-06-03 | — | — | US | disclosed |
| US-6737437-B2 | FOR EXAMPLE, 7-(2S-(3R-HYDROXY-4-PHENYLBUTYL)-5-OXOPYRROLIDIN -1-YL)HEPTANOIC ACID; PROMOTING BONE READSORPTION; BONE LOSS, FRACTURES, AND DEFECTS; FRAILTY; CHILDHOOD IDIOPATHIC BONE LOSS; ALVEOLAR BONE LOSS, OSTEOTOMY; GUM DISEASE; PROSTHETICS | PFIZER INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1417975-A1 | REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-05-12 | — | — | EP | disclosed |
| EP-1409455-A1 | PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| WO-2004019938-A1 | OXAZOLIDIN-2-ONE AND THIAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2004-03-11 | — | — | WO | disclosed |
| EP-1389107-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2004012773-A1 | POLYALKYLENE GLYCOL ACID ADDITIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| US-6686360-B2 | ANTIISCHEMIC AGENTS | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| EP-1069104-B1 | PROCESS FOR PRODUCING HINOKITIOL | ASAHI CHEMICAL IND (JP) | 2004-01-28 | — | — | EP | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6649657-B2 | Administering amide to treat osteoporosis | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030207925-A1 | Methods of treatment with selective EP4 receptor agonists | CAMERON KIMBERLY O (US) | 2003-11-06 | — | — | US | disclosed |
| US-6642266-B2 | Therapy of condition which presents with low bone mass in a mammal comprising administering to mammal an EP4 (prostaglandins) receptor selective agonist or prodrug | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| WO-2003080554-A2 | IODINATED TRIGLYCERIDE ANALOGS | FUJI PHOTO FILM CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
| WO-2003077910-A1 | METHODS OF TREATMENT WITH SELECTIVE EP4 RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003074575-A1 | POLYMERIZABLE COMPOUND, POLYMER COMPOUND, COMPOSITION USING SUCH COMPOUND, AND IMAGE FORMING METHOD AND APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2003-09-12 | — | — | WO | disclosed |
| EP-1339678-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030158207-A1 | N-benzylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2003-08-21 | — | — | US | disclosed |
| US-20030149086-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O (US) | 2003-08-07 | — | — | US | disclosed |
| US-6586475-B1 | 5-chloro-N-(2-N,N-diethylamino)ethyl)-2- methoxy-4-(1-naphthoylamino)benzamide and prodrugs, used for prevention of neurodegenarative diseases such as Alzheimer's disease | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20030120079-A1 | Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction | SYNTEX (U.S.A.) LLC | 2003-06-26 | — | — | US | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1318140-A1 | NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS | Mitsubishi Pharma Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLEY Q (US) | 2003-06-05 | — | — | US | disclosed |
| US-6562846-B2 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | disclosed |
| US-6552067-B2 | For therapy of osteoporosis, frailty, an osteoporotic fracture, a bone defect, childhood idiopathic bone loss, alveolar bone loss, mandibular bone loss, bone fracture, osteotomy, bone loss associated with periodontitis | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| EP-0874808-B1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LAB (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| WO-2003008377-A1 | PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
| US-20020188009-A1 | Bisarylimidazolyl fatty acid amide hydrolase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-12 | — | — | US | disclosed |
| US-6492412-B2 | ADMINISTERING TO A MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF SULFONAMIDE OR ALKANOY OR AMIDE DERIVATIVE CONTAINING HETERO OR AROMATIC RINGS TO TREAT OSTEOPOROSIS, OSTEOTOMY, CHILDHOOD IDIOPATHIC BOEN LOSS ETC. | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020177594-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-11-28 | — | — | US | disclosed |
| WO-2002087569-A1 | BISARYLIMIDAZOLYL FATTY ACID AMIDE HYDROLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
| US-6451827-B2 | MODULATING BLOOD GLUCOSE CONCENTRATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-6441165-B2 | 11-KETO-3-CHLORO-6,11-DIHYDRO-5,5-DIOXO-6-METHYL-DIBENZO(C,F)( 1,2)THIAZEPINE IS REACTED WITH SODIUM BOROHYDRIDE IN PRESENCE OF CHLORINATED SOLVENT AND A CATALYST TO FORM ALCOHOL, THEN CHLORINATING TO FORM CHLORIDE, FINALLY FORMING A SALT | LES LABORATORIES SERVIER (FR) | 2002-08-27 | — | — | US | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| US-20020103192-A1 | Inhibitors of histone deacetylase | ABBOTT LABORATORIES | 2002-08-01 | — | — | US | disclosed |
| EP-1226104-A1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002046129-A2 | INHIBITORS OF HISTONE DEACETYLASE | ABBOTT LABORATORIES (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020065308-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | LOTUS PHARMACEUTICAL CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| WO-2002042268-A2 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | disclosed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| US-20010037021-A1 | Process for the preparation of 11-amino-3-chloro-6,11-dihydro-5,5-dioxo-6-methyl-dibenzo[c,f][1,2]thiazepine and application to the synthesis of tianeptine | LES LABORATOIRES SERVIER (FR) | 2001-11-01 | — | — | US | disclosed |
| US-6310255-B1 | Process for producing hinokitiol | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2001-10-30 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
| EP-1132376-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2001-09-12 | — | — | EP | disclosed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | disclosed |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-08-30 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2001032596-A1 | PHENOXY CARBOXYLIC ACID COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
| US-6214877-B1 | ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1069104-A1 | PROCESS FOR PRODUCING HINOKITIOL | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-0626969-B1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2000-05-24 | — | — | EP | disclosed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | disclosed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | disclosed |
| US-6013823-A | AS CHEMICAL INTERMEDIATES; UTROTONIC AGENTS, BRONCHODIALATORS | NEW PHARMA INTERNATIONAL CORP. (UY) | 2000-01-11 | — | — | US | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5942622-A | NOVEL COMPOUNDS FOR TREATING ILLNESS RESULTING FROM ABNORMAL STIMULATION OF ENDOTHELIAL RECEPTORS; FOR EXAMPLE: 4-((6-CHLORO-1,3-BENZODIOXOL-5-YL)METHYL)-1-(CYCLOHEXYLMETHYL) -3-(2-PYRIDINYL)-1H-PYRAZOLE-5-CARBOXYLATE | HOECHST MARION ROUSSEL (FR) | 1999-08-24 | — | — | US | disclosed |
| EP-0874808-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | Abbott Laboratories (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5817694-A | OXYTOCICS | NEW PHARMA INTERNATIONAL CORP. (UY) | 1998-10-06 | — | — | US | disclosed |
| EP-0857171-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-08-12 | — | — | EP | disclosed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0637318-B1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA GEIGY AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| US-5707982-A | ANTITUMOR | ROUSSEL UCLAF (FR) | 1998-01-13 | — | — | US | disclosed |
| EP-0815076-A1 | PROCESS FOR PREPARING PROSTAGLANDIN E1, E2 AND ANALOGS THEREOF USING FURYLCOPPER REAGENTS | Vivus, Inc. (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5686564-A | Peptide derivatives corresponding to the carboxy terminal sequence of hirudin | NOVARTIS CORPORATION (US) | 1997-11-11 | — | — | US | disclosed |
| US-5665777-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0574185-B1 | PGE1 analogs | NEWPHARMA INTERNATIONAL CORP (UY) | 1997-09-03 | — | — | EP | disclosed |
| US-5663053-A | COENZYME A TRANSACYLASE FOR SCREENING | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5648373-A | CoA-IT and PAF inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997018188-A1 | BIPHENYL HYDROXAMATE INHIBITORS OF MATRIX METALLOPROTEINASES | ABBOTT LABORATORIES (US) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997015555-A2 | IMIDAZOLE DERIVATIVES AND THE USE THEREOF AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| US-5618959-A | Process for preparing prostaglandin E1, E2 and analogs thereof using furylcopper reagents | VIVUS INCORPORATED (US) | 1997-04-08 | — | — | US | disclosed |
| WO-1996028419-A1 | PROCESS FOR PREPARING PROSTAGLANDIN E1, E2 AND ANALOGS THEREOF USING FURYLCOPPER REAGENTS | VIVUS, INCORPORATED (US) | 1996-09-19 | — | — | WO | disclosed |
| US-5492915-A | ANTIINFLAMMATORY AGENTS | RHONE-POULENC RORER S.A. (FR) | 1996-02-20 | — | — | US | disclosed |
| US-5434186-A | Antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0626969-A4 | CoA-IT AND PAF INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0637318-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | Novartis AG (CH) | 1995-02-08 | — | — | EP | disclosed |
| EP-0626969-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5366982-A | Antiinflammatory agents or antihistamines | RHONE-POULENC RORER S.A. (FR) | 1994-11-22 | — | — | US | disclosed |
| US-5273999-A | A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0574185-A2 | PGE1 analogs | NEWPHARMA INTERNATIONAL CORPORATION (UY) | 1993-12-15 | — | — | EP | disclosed |
| WO-1993022344-A1 | PEPTIDE DERIVATIVES CORRESPONDING TO THE CARBOXY TERMINAL SEQUENCE OF HIRUDIN | CIBA-GEIGY AG (CH) | 1993-11-11 | — | — | WO | disclosed |
| WO-1993016674-A1 | CoA-IT AND PAF INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
| EP-0550502-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| EP-0412110-B1 | NOVEL VITAMIN D ANALOGUES | LEO PHARM PROD LTD (DK) | 1993-07-07 | — | — | EP | disclosed |
| EP-0548227-A1 | COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-06-30 | — | — | EP | disclosed |
| EP-0540604-A1 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | Aventis Pharma S.A. (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-5206229-A | Inhibit cell proliferation, antiinflammatory, treating imbalance of immune system | LEO PHARMACEUTICAL PRODUCTS LTD (DK) | 1993-04-27 | — | — | US | disclosed |
| EP-0531823-A1 | Bicyclic carboxylic acid derivatives as anti-inflammatory agents | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-17 | — | — | EP | disclosed |
| WO-1992004334-A1 | COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004330-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992001675-A2 | SUBSTITUTED BICYCLIC BIS-ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | RHONE-POULENC RORER S.A. (FR) | 1992-02-06 | — | — | WO | disclosed |
| US-5057524-A | Asthma, dermatitis | A. H. ROBINS COMPANY INCORPORATED (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0412110-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1991-02-13 | — | — | EP | disclosed |
| US-4962106-A | Treating platelet activating factor mediated disorders | G. D. SEARLE & CO. (US) | 1990-10-09 | — | — | US | disclosed |
| US-4885373-A | AMINE DERVIVATIVES USED AS ANTIDEPRESSANT AND DOPAMINERGIC STIMULANTS | ADIR ET CIE (FR) | 1989-12-05 | — | — | US | disclosed |
| WO-1989010351-A1 | NOVEL VITAMIN D ANALOGUES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1989-11-02 | — | — | WO | disclosed |
| US-4871720-A | Aromatically substituted azacycloalkyl-alkanediphosphonic acids useful for the treatment of illnesses that can be attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| US-4863951-A | ANTIDEPRESSANTS, ANTIAGRESSIVES, DOPAMINERGIC PROPERTIES | ADIR ET CIE (FR) | 1989-09-05 | — | — | US | disclosed |
| US-4804658-A | PLATELET-ACTIVATING FACTOR ANTAGONISTS | G. D. SEARLE & CO. (US) | 1989-02-14 | — | — | US | disclosed |
| US-4758573-A | Heterocyclic group-containing compounds | G. D. SEARLE & CO. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0260613-A2 | Imidazopyridine derivatives, their preparation and their use as PAF-antagonists | G.D. Searle & Co. (US) | 1988-03-23 | — | — | EP | disclosed |
| US-4695647-A | RADIOACTIVE MATERIALS | DRUG SCIENCE FOUNDATION (US) | 1987-09-22 | — | — | US | disclosed |
| US-4680414-A | Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones | MERCK & CO., INC. (US) | 1987-07-14 | — | — | US | disclosed |
| EP-0089065-B1 | NOVEL PHENYLPIPERAZINE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1987-06-16 | — | — | EP | disclosed |
| EP-0105575-B1 | 1-(1H-IMIDAZOLYL), 1-N-MORPHOLINYL AND PYRIDYL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | G.D. Searle & Co. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4634717-A | BRIAN INJURY | MERCK & CO., INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4605663-A | BRAIN TRAUMA | MERCK & CO., INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4605664-A | BRAIN TRAUMA | MERCK & CO., INC. (US) | 1986-08-12 | — | — | US | disclosed |
| EP-0054924-B1 | PHARMACEUTICAL COMPOUNDS, THEIR PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-08-06 | — | — | EP | disclosed |
| US-4604403-A | Use of substituted-3(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treating grey matter edema | MERCK & CO., INC. (US) | 1986-08-05 | — | — | US | disclosed |
| US-4596821-A | Brain disorders | MERCK & CO., INC. (US) | 1986-06-24 | — | — | US | disclosed |
| US-4579862-A | TREATMENT OF CEREBROVASCULAR DISEACE, ISCHEMIA, DIABETES, ANGINA, MYOCARDIAL INFARCTION | G. D. SEARLE & CO. (US) | 1986-04-01 | — | — | US | disclosed |
| US-4578465-A | VASODILATION AGENTS, HYPOTENSIVE AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1986-03-25 | — | — | US | disclosed |
| US-4576962-A | Prostaglandin analogues | THE PROCTER & GAMBLE COMPANY (US) | 1986-03-18 | — | — | US | disclosed |
| EP-0160891-A1 | Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-Hydroxy-1H-Pyrrole-2,5-diones, their analogs and their salts | MERCK & CO. INC. (US) | 1985-11-13 | — | — | EP | disclosed |
| US-4535183-A | PALLIATION OF SICKLE CELL ANEMIA, RESPIRATORY DISORDERS, HYPOXIA, RADIOSENSITIZATION OF TUMORS | BURROUGHS WELLCOME CO. (US) | 1985-08-13 | — | — | US | disclosed |
| US-4530933-A | 8-Aza-13-thiaprostanoids and a method of use thereof as anti-ulcer agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-07-23 | — | — | US | disclosed |
| US-4524151-A | 7-Oxabicycloheptane thio ethers useful as cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1985-06-18 | — | — | US | disclosed |
| US-4486443-A | PROSTAGLANDIN-LIKE EFFECTS | BURROUGHS WELLCOME CO. (US) | 1984-12-04 | — | — | US | disclosed |
| EP-0001238-B1 | HYDANTOIN DERIVATIVES, THEIR SYNTHESIS, PHARMACEUTICAL FORMULATIONS AND INTERMEDIATES IN THEIR PREPARATION | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-07-04 | — | — | EP | disclosed |
| EP-0108451-A2 | Novel prostaglandin analogues | THE PROCTER & GAMBLE COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
| EP-0105575-A1 | 1-(1H-imidazolyl), 1-N-morpholinyl and pyridyl compounds, their preparation and pharmaceutical compositions containing them | G.D. Searle & Co. (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4439365-A | TRIPHENYLMETHOXY ALKENYLMAGNESIUM HALIDES | AMERICAN CYANAMID COMPANY (US) | 1984-03-27 | — | — | US | disclosed |
| US-4438115-A | PIPERAZINE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1984-03-20 | — | — | US | disclosed |
| EP-0042162-B1 | COMPOSITIONS FOR TREATING DISEASES IN CIRCULATORY ORGANS | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-11-23 | — | — | EP | disclosed |
| EP-0089065-A2 | Novel phenylpiperazine derivatives and process for producing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-09-21 | — | — | EP | disclosed |
| US-4343949-A | PROSTAGLANDIN REARRANGEMENTS | AMERICAN CYANAMID COMPANY (US) | 1982-08-10 | — | — | US | disclosed |
| EP-0054924-A2 | Pharmaceutical compounds, their preparation and use | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-06-30 | — | — | EP | disclosed |
| US-4337353-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | ROUSSEL UCLAF (FR) | 1982-06-29 | — | — | US | disclosed |
| US-4337262-A | HYPOTENSIVE AGENT, ANTICOAGULANT, VASODILATION, ANTIULCER AGENT, BRONCHODILATOR AGENT, ANTIALLERGEN, AND CONTRACEPTIVE | BURROUGHS WELLCOME CO. (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0002258-B1 | HYDANTOIN DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS AND INTERMEDIATES, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1982-02-17 | — | — | EP | disclosed |
| EP-0042162-A2 | Compositions for treating diseases in circulatory organs | Chugai Seiyaku Kabushiki Kaisha (JP) | 1981-12-23 | — | — | EP | disclosed |
| US-4293704-A | Novel 2-substituted-3,4-epoxycyclopentan-1-ones, 2-substituted-3,4-epoxycyclopentan-1-ols, and various 2-substituted-cyclopentenones | AMERICAN CYANAMID COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4289707-A | Nitrogen heterocycles | BURROUGHS WELLCOME CO. (US) | 1981-09-15 | — | — | US | disclosed |
| US-4262128-A | HAVING PROSTAGLANDIN-LIKE BIOLOGICAL PROPERTIES | BURROUGHS WELLCOME CO. (US) | 1981-04-14 | — | — | US | disclosed |
| US-4254043-A | Method for the acylation of heterocyclic compounds | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| US-4237316-A | ISOMERIZATION OF PROSTAGLANDIN INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1980-12-02 | — | — | US | disclosed |
| US-4204068-A | Nitrogen heterocycles | BURROUGHS WELLCOME CO. (US) | 1980-05-20 | — | — | US | disclosed |
| EP-0006718-A1 | 1.2.4-Triazolidine-3.5-dione derivatives, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
| US-4179574-A | PROSTAGLANDIN INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4177346-A | 1,5-Disubstituted-2-pyrrolidones | PFIZER INC. (US) | 1979-12-04 | — | — | US | disclosed |
| EP-0002258-A2 | Hydantoin derivatives and salts thereof, their synthesis and intermediates, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-06-13 | — | — | EP | disclosed |
| US-4155908-A | PSORIASIS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
| EP-0001238-A1 | Hydantoin derivatives, their synthesis, pharmaceutical formulations and intermediates in their preparation | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-04-04 | — | — | EP | disclosed |
| US-4142056-A | MULTISTAGE PROCESS FOR PREPARING 2-(6'-CARBOMETHOXYHEXYL)-2-CYCLOPENTEN-1-ONE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4142056-A | MULTISTAGE PROCESS FOR PREPARING 2-(6'-CARBOMETHOXYHEXYL)-2-CYCLOPENTEN-1-ONE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4128564-A | 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins | MERCK & CO., INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126629-A | FERTILITY CONTROL | MERCK & CO., INC. (US) | 1978-11-21 | — | — | US | disclosed |
| US-4123456-A | BRONCHODILATORS, HYPOTENSIVES, ANTIULCER, ANTISECRETORY, MICROBIOCIDES, ANTICONVULSANTS, OXYTOCICS, ANALGESICS, DIURETICS, ANTIINFLAMMATORY, ANTICOAGULANTS | AMERICAN CYANAMID COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4110368-A | PROSTAGLANDINS, BRONCHODILATOR, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1978-08-29 | — | — | US | disclosed |
| US-4097504-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4094896-A | HYPOTENSIVE AGENTS, BACTERICIDES AND FUNGICIDES | AMERICAN CYANAMID COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4092356-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4091107-A | RENAL VASODILATORS, ANTICLOTTING AGENTS, GROWTH HORMONE RELEASE, REGULATORS OF IMMUNE RESPONSE | MERCK & CO., INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4088536-A | ALKYLATING LITHIUM CYCLOPENTADIENE, OXYGENATING TO PRODUCE HYDROXYCLYCLOPENTENONES, SEPARATION, MULTISTAGE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1978-05-09 | — | — | US | disclosed |
| US-4088536-A | ALKYLATING LITHIUM CYCLOPENTADIENE, OXYGENATING TO PRODUCE HYDROXYCLYCLOPENTENONES, SEPARATION, MULTISTAGE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1978-05-09 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4076732-A | Derivatives of α-(6-carboxyhexyl) furfuryl alcohol | AMERICAN CYANAMID COMPANY (US) | 1978-02-28 | — | — | US | disclosed |
| US-4074056-A | ANTIMICROBIAL, HYPOTENSIVE, AND ANTIULCER AGENTS, INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4066692-A | 11,12-SECOPROSTAGLANDINS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4061672-A | Derivatives of 9-hydroxy-13-trans-prostenoic acid | AMERICAN CYANAMID COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061643-A | ANTIFERTILITY | MERCK & CO., INC. (US) | 1977-12-06 | — | — | US | disclosed |
| US-4060540-A | BRONCHODILATORS, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1977-11-29 | — | — | US | disclosed |
| US-4059602-A | HYPOTENSIVE, VASODILATION, ANTITHROMBOSIS | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4059601-A | VASODILATION, HYPOTENSIVE, ANTITHROMBOSIS | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-RE29469-E | PROSTAGLANDINS; BRONCHODILATORS, HYPOTENSIVES, ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
| US-4055597-A | RENAL VASODILATORS | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4055596-A | PHARMACEUTICALS | MERCK & CO., INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4054741-A | Derivatives of prostanoic acid | AYERST MCKENNA & HARRISON LTD. (CA) | 1977-10-18 | — | — | US | disclosed |
| US-4054604-A | MICROBIOCIDES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-10-18 | — | — | US | disclosed |
| US-4046787-A | ANTIULCER AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-09-06 | — | — | US | disclosed |
| US-4046801-A | 13-Cis prostaglandin derivatives | SYNTEX (U.S.A.) INC. (US) | 1977-09-06 | — | — | US | disclosed |
| US-4044043-A | HYPERTENSIVE AGENTS, MICROBIOCIDES | AMERICAN CYANAMID COMPANY (US) | 1977-08-23 | — | — | US | disclosed |
| US-4033996-A | RENAL VASODILATORS, ANTITHROMBOSIS, GROWTH HORMONE RELEASING | MERCK & CO., INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-4032533-A | PROSTAGLANDIN MIMICS OR ANTAGONISTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-06-28 | — | — | US | disclosed |
| US-4031129-A | LITHIUM CYCLOPENTADIENE, ETHYL-7-BROMOHEPTANOATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4031129-A | LITHIUM CYCLOPENTADIENE, ETHYL-7-BROMOHEPTANOATE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-06-21 | — | — | US | disclosed |
| US-4020177-A | CONTRACEPTIVES | MERCK & CO., INC. (US) | 1977-04-26 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
| US-4018811-A | MICROBIOCIDES, ANTIULCER, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-04-19 | — | — | US | disclosed |
| US-4017534-A | BRONCHODILATION, ANTISECRETORY | AMERICAN CYANAMID COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4007210-A | PROSTANOIC ACID DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1977-02-08 | — | — | US | disclosed |
| US-4006179-A | HYPOTENSIVE AGENTS, MICROBIOCIDES | AMERICAN CYANAMID COMPANY (US) | 1977-02-01 | — | — | US | disclosed |
| US-4003911-A | ANTISECRETORY AGENTS, OXYTOCICS, BRONCHODILATORS, PLASTICIZERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-01-18 | — | — | US | disclosed |
| US-3991106-A | FOR ESTRUS SYNCHRONIZATION AND TREATMENT OF INFERTILITY | MERCK & CO., INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3991087-A | RENAL VASODILATORS, HYPOTENSIVE AGENTS, ANTITHROMBOTICS | MERCK & CO., INC. (US) | 1976-11-09 | — | — | US | disclosed |
| US-3987091-A | RENAL VASODILATORS | MERCK & CO., INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3981868-A | MICROBIOCIDES, HYPOTENSIVE AGENTS | AMERICAN CYANAMID COMPANY (US) | 1976-09-21 | — | — | US | disclosed |
| US-3966773-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3950406-A | BRONCHODILATORS, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
| US-3932463-A | BRONCHODILATORS, GASTRIC ACID SECRETION INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932463-A | BRONCHODILATORS, GASTRIC ACID SECRETION INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932472-A | INHIBITORS OF GASTRIC ACID SECRETION | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
| US-3932479-A | BRONCHODILATOR, HYPOTENSIVE, ANTIULCER | AMERICAN CYANAMID COMPANY (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | HDAC1, HDAC2, HDAC5 | CYP1A2 3817/4885ALDH1A1 1427/4885TRPA1 4677/4885 |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP1A2 26/4885ALDH1A1 378/4885TRPA1 3036/4885 |
| US-20220024916-A1 | HETEROCYCLIC COMIPOUND AS CDK-HDAC DUAL PATHWAY INHIBITOR | HDAC1, HDAC3, HDAC2 | CYP1A2 2505/4885ALDH1A1 1690/4885TRPA1 4744/4885 |
| US-20040176461-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP1A2 2335/4885ALDH1A1 2216/4885TRPA1 3625/4885 |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | CYP1A2 599/4885ALDH1A1 3544/4885TRPA1 4672/4885 |
| US-20210024692-A1 | METHOD FOR PRODUCING MULTI-ARM TYPE POLYETHYLENE GLYCOL DERIVATIVE | ADH1A, ADH1C, ADH5 | CYP1A2 242/4885ALDH1A1 143/4885TRPA1 4833/4885 |
| US-20020103192-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC4 | CYP1A2 2067/4885ALDH1A1 546/4885TRPA1 4593/4885 |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | CYP1A2 4753/4885ALDH1A1 3415/4885TRPA1 4812/4885 |
| US-10195156-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | CYP1A2 4874/4885ALDH1A1 4687/4885TRPA1 3751/4885 |
| US-20090076022-A1 | epidermal growth factor receptor tyrosine kinase (EGFR-TK) and histone deacetylase inhibitors such as 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide, used as anticarcinogenic agents | EGFR, HDAC1, HDAC8 | CYP1A2 3772/4885ALDH1A1 1941/4885TRPA1 2967/4885 |
| US-20080312317-A1 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES | HDAC11, HDAC1, HDAC3 | CYP1A2 2726/4885ALDH1A1 2190/4885TRPA1 3902/4885 |
| US-20050209336-A1 | EP2 receptor agonists | PTGER2, PTGER1, PTGER3 | CYP1A2 315/4885ALDH1A1 1586/4885TRPA1 180/4885 |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | CYP1A2 4789/4885ALDH1A1 1006/4885TRPA1 1244/4885 |
| US-20180305403-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | CYP1A2 1442/4885ALDH1A1 1520/4885TRPA1 1536/4885 |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP1A2 2335/4885ALDH1A1 2216/4885TRPA1 3625/4885 |
| US-20040192743-A1 | Substituted azole derivatives as therapeutic agents | PTPRS, PTPRO, PTPRJ | CYP1A2 472/4885ALDH1A1 710/4885TRPA1 4081/4885 |
| US-20240174637-A1 | DEGRADERS OF GRK2 AND USES THEREOF | GRK2, GRK3, GRK1 | CYP1A2 432/4885ALDH1A1 2710/4885TRPA1 3111/4885 |
| US-20050002864-A1 | 1,3-glyceride compound having two iodophenyl groups | SGMS1, PHOSPHO1, SGMS2 | CYP1A2 1702/4885ALDH1A1 2054/4885TRPA1 2604/4885 |
| US-20140315889-A1 | HYDROXAMATE DERIVATIVES FOR HDAC INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | HDAC1, HDAC5, HDAC3 | CYP1A2 2828/4885ALDH1A1 772/4885TRPA1 1750/4885 |
| US-20030105092-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | CYP1A2 2335/4885ALDH1A1 2216/4885TRPA1 3625/4885 |
| US-20140235671-A1 | SCRIPTAID ISOSTERES AND THEIR USE IN THERAPY | QARS1, C1QBP, QTRT1 | CYP1A2 1095/4885ALDH1A1 2818/4885TRPA1 1332/4885 |
| US-20150210745-A1 | Double-Acylated GLP-1 Derivatives with a Linker | GLP1R, VIP, IAPP | CYP1A2 3742/4885ALDH1A1 3185/4885TRPA1 4027/4885 |
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | CYP1A2 1931/4885ALDH1A1 1664/4885TRPA1 2182/4885 |
| US-20080138285-A1 | Compound comprising a fluorine-substituted alkyl group and a liposome contrast medium comprising the compound | PHOSPHO1, SGMS1, SGMS2 | CYP1A2 4180/4885ALDH1A1 4870/4885TRPA1 909/4885 |
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | CYP1A2 1700/4885ALDH1A1 1531/4885TRPA1 4267/4885 |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | GOT2, ACER2, GOT1 | CYP1A2 2478/4885ALDH1A1 1033/4885TRPA1 2210/4885 |
| US-20130131354-A1 | Naphthocyanines for Use as Contrast Agents | NPM1, UACA, INCENP | CYP1A2 3267/4885ALDH1A1 2599/4885TRPA1 996/4885 |
| US-20100261710-A1 | HDAC Inhibitors | HDAC5, HDAC1, HDAC4 | CYP1A2 3702/4885ALDH1A1 667/4885TRPA1 3821/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | CYP1A2 944/4885ALDH1A1 836/4885TRPA1 438/4885 |
| US-20210198200-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | LNPK, PLTP, PHOSPHO1 | CYP1A2 4874/4885ALDH1A1 4687/4885TRPA1 3751/4885 |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | CYP1A2 4817/4885ALDH1A1 2328/4885TRPA1 4712/4885 |
| US-20130190523-A1 | Process for the Preparation of Oxidized Phospholipids | PHOSPHO1, SGMS1, SGMS2 | CYP1A2 1590/4885ALDH1A1 1878/4885TRPA1 4787/4885 |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | ABAT, AADAT, AADAC | CYP1A2 767/4885ALDH1A1 210/4885TRPA1 654/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | CYP1A2 3083/4885ALDH1A1 2459/4885TRPA1 3432/4885 |
| US-20080027112-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | CYP1A2 951/4885ALDH1A1 890/4885TRPA1 3547/4885 |
| US-20110305729-A1 | Scriptaid Isosteres and Their Use in Therapy | QARS1, C1QBP, C1S | CYP1A2 983/4885ALDH1A1 2869/4885TRPA1 1294/4885 |
| US-20200062782-A1 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | SNCA, PARK7, SYNJ2 | CYP1A2 4686/4885ALDH1A1 2050/4885TRPA1 4095/4885 |
| US-20150152157-A1 | Double-Acylated GLP-1 Derivatives | GLP1R, GIPR, GPR119 | CYP1A2 1704/4885ALDH1A1 3068/4885TRPA1 3179/4885 |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | CYP1A2 1467/4885ALDH1A1 1479/4885TRPA1 1184/4885 |
| US-20080125448-A1 | Quinazoline Based EGFR Inhibitors Containing a Zinc Binding Moiety | EGFR, ERBB2, ERBB4 | CYP1A2 2843/4885ALDH1A1 3957/4885TRPA1 3447/4885 |
| US-20170145069-A1 | GLP-1 Derivatives | GLP1R, GIPR, GCG | CYP1A2 3749/4885ALDH1A1 3868/4885TRPA1 3622/4885 |
| US-10336770-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | CYP1A2 4753/4885ALDH1A1 3415/4885TRPA1 4812/4885 |
| US-20090312377-A1 | DERIVATIVES OF BENZO[D]ISOTHIAZOLES AS HISTONES DEACETYLASE INHIBITORS | HDAC1, HDAC2, HDAC3 | CYP1A2 939/4885ALDH1A1 273/4885TRPA1 3610/4885 |
| US-20100120876-A1 | COMPOUNDS, METHODS AND FORMULATIONS FOR THE ORAL DELIVERY OF A GLUCAGON-LIKE PEPTIDE (GLP-1) COMPOUND OR A MELANOCORTIN-4 RECEPTOR (MC4) AGONIST PEPTIDE | MC4R, GLP1R, MC3R | CYP1A2 4367/4885ALDH1A1 4814/4885TRPA1 1885/4885 |
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | SNRPA, F12, ABCB4 | CYP1A2 3333/4885ALDH1A1 1403/4885TRPA1 2620/4885 |
| US-20140066419-A1 | HYDROXAMIC ACID DERIVATIVES | HDAC5, HDAC7, HDAC4 | CYP1A2 2759/4885ALDH1A1 1017/4885TRPA1 3896/4885 |
| US-20100317881-A1 | PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | PHOSPHO1, SGMS1, SGMS2 | CYP1A2 1553/4885ALDH1A1 2028/4885TRPA1 4754/4885 |
| US-20080234297-A1 | HSP90 Inhibitors Containing a Zinc Binding Moiety | HSP90AB1, HSP90AB2P, HSP90B1 | CYP1A2 3984/4885ALDH1A1 1822/4885TRPA1 3726/4885 |
| US-20090163560-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | CYP1A2 1178/4885ALDH1A1 1555/4885TRPA1 3306/4885 |
| US-11261195-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | BAZ2A, BAZ2B, PI4KB | CYP1A2 4753/4885ALDH1A1 3415/4885TRPA1 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.